These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 25752908)

  • 41. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.
    Nasti G; Piccirillo MC; Izzo F; Ottaiano A; Albino V; Delrio P; Romano C; Giordano P; Lastoria S; Caracò C; de Lutio di Castelguidone E; Palaia R; Daniele G; Aloj L; Romano G; Iaffaioli RV
    Br J Cancer; 2013 Apr; 108(8):1566-70. PubMed ID: 23558891
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review.
    Bolhuis K; Kos M; van Oijen MGH; Swijnenburg RJ; Punt CJA
    Eur J Cancer; 2020 Dec; 141():225-238. PubMed ID: 33189037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases.
    Hubert C; Lucidi V; Weerts J; Dili A; Demetter P; Massart B; Komuta M; Navez J; Reding R; Gigot JF; Sempoux C
    Eur J Surg Oncol; 2018 Oct; 44(10):1532-1538. PubMed ID: 30093084
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
    Cremolini C; Milione M; Marmorino F; Morano F; Zucchelli G; Mennitto A; Prisciandaro M; Lonardi S; Pellegrinelli A; Rossini D; Bergamo F; Aprile G; Urbani L; Morelli L; Schirripa M; Cardellino GG; Fassan M; Fontanini G; de Braud F; Mazzaferro V; Falcone A; Pietrantonio F
    Br J Cancer; 2018 Apr; 118(7):955-965. PubMed ID: 29531324
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab.
    Basso M; Dadduzio V; Ardito F; Lombardi P; Strippoli A; Vellone M; Orlandi A; Rossi S; Cerchiaro E; Cassano A; Giuliante F; Barone C
    Medicine (Baltimore); 2016 May; 95(20):e3722. PubMed ID: 27196492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Gruenberger B; Tamandl D; Schueller J; Scheithauer W; Zielinski C; Herbst F; Gruenberger T
    J Clin Oncol; 2008 Apr; 26(11):1830-5. PubMed ID: 18398148
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases.
    Pietrantonio F; Mazzaferro V; Miceli R; Cotsoglou C; Melotti F; Fanetti G; Perrone F; Biondani P; Muscarà C; Di Bartolomeo M; Coppa J; Maggi C; Milione M; Tamborini E; de Braud F
    Med Oncol; 2015 Jul; 32(7):182. PubMed ID: 26003673
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.
    Feng QY; Wei Y; Chen JW; Chang WJ; Ye LC; Zhu DX; Xu JM
    World J Gastroenterol; 2014 Apr; 20(15):4263-75. PubMed ID: 24764664
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases.
    Berardi G; De Man M; Laurent S; Smeets P; Tomassini F; Ariotti R; Hoorens A; van Dorpe J; Varin O; Geboes K; Troisi RI
    Eur J Surg Oncol; 2018 Jul; 44(7):1069-1077. PubMed ID: 29615295
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH; Park SH; Lee J; Kim TW; Hong YS; Kim KP; Kim SY; Baek JY; Kang HJ; Shin SJ; Shim BY; Park YS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):223-30. PubMed ID: 23689915
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
    Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
    Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009).
    Zinser-Sierra JW; Rodríguez-Ramírez S; Villalobos-Valencia R; Ramírez-Márquez M
    Drugs R D; 2011; 11(2):101-11. PubMed ID: 21679003
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Neoadjuvant therapy concepts for liver metastases].
    Folprecht G; Bechstein WO
    Chirurg; 2011 Nov; 82(11):989-94. PubMed ID: 22033894
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable colorectal liver metastases?: A systematic review.
    Okuno M; Hatano E; Nishino H; Seo S; Taura K; Uemoto S
    Eur J Surg Oncol; 2017 Jun; 43(6):1003-1012. PubMed ID: 27624917
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Conversion therapy in patients with colorectal liver metastases.
    Villard C; Habib M; Nordenvall C; Nilsson PJ; Jorns C; Sparrelid E
    Eur J Surg Oncol; 2021 Aug; 47(8):2038-2045. PubMed ID: 33640172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Radiofrequency Ablation to Improve Survival After Conversion Chemotherapy for Colorectal Liver Metastases.
    Nielsen K; Scheffer HJ; Volders JH; van der Vorst MJ; van Tilborg AA; Comans EF; de Lange-de Klerk ES; Sietses C; Meijer S; Meijerink MR; van den Tol MP
    World J Surg; 2016 Aug; 40(8):1951-8. PubMed ID: 27220509
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The COMET Open-label Phase II Study of Neoadjuvant FOLFOX or XELOX Treatment Combined with Molecular Targeting Monoclonal Antibodies in Patients with Resectable Liver Metastasis of Colorectal Cancer.
    Kataoka M; Kanda M; Ishigure K; Matsuoka H; Sato Y; Takahashi T; Tanaka C; Deguchi T; Shibata Y; Sato M; Inagaki H; Matsui T; Kondo A; Takano N; Tanaka H; Sakamoto J; Oba K; Kondo K
    Ann Surg Oncol; 2017 Feb; 24(2):546-553. PubMed ID: 27638675
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases.
    Beppu T; Hayashi N; Masuda T; Komori H; Horino K; Hayashi H; Okabe H; Baba Y; Kinoshita K; Akira C; Watanebe M; Takamori H; Baba H
    Anticancer Res; 2010 Mar; 30(3):1015-20. PubMed ID: 20393029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival.
    Yasuno M; Uetake H; Ishiguro M; Mizunuma N; Komori T; Miyata G; Shiomi A; Kagimura T; Sugihara K
    Int J Clin Oncol; 2019 May; 24(5):516-525. PubMed ID: 30612267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.